Global Anti-VEGF Therapeutic Production, Demand and Key Producers, 2022-2028
Anti–vascular endothelial growth factor therapy, also known as anti-VEGF therapy or medication, is the use of medications that block vascular endothelial growth factor.
This report studies the global Anti-VEGF Therapeutic production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Anti-VEGF Therapeutic, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2021 as the base year. This report explores demand trends and competition, as well as details the characteristics of Anti-VEGF Therapeutic that contribute to its increasing demand across many markets.
The global Anti-VEGF Therapeutic market size is expected to reach $ million by 2028, rising at a market growth of % CAGR during the forecast period (2022-2028).
Highlights and key features of the study
Global Anti-VEGF Therapeutic total production and demand, 2017-2028, (K Units)
Global Anti-VEGF Therapeutic total production value, 2017-2028, (USD Million)
Global Anti-VEGF Therapeutic production by region & country, production, value, CAGR, 2017-2028, (USD Million) & (K Units)
Global Anti-VEGF Therapeutic consumption by region & country, CAGR, 2017-2028 & (K Units)
U.S. VS China: Anti-VEGF Therapeutic domestic production, consumption, key domestic manufacturers and share
Global Anti-VEGF Therapeutic production by manufacturer, production, price, value and market share 2017-2022, (USD Million) & (K Units)
Global Anti-VEGF Therapeutic production by Type, production, value, CAGR, 2017-2028, (USD Million) & (K Units)
Global Anti-VEGF Therapeutic production by Application production, value, CAGR, 2017-2028, (USD Million) & (K Units)
This reports profiles key players in the global Anti-VEGF Therapeutic market based on the following parameters – headquarters, production locations, products portfolio, Anti-VEGF Therapeutic revenue, sales, average price and gross margin, recent developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Anti-VEGF Therapeutic market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2017-2028 by year with 2021 as the base year, 2022 as the estimate year, and 2028 as the forecast year.
Global Anti-VEGF Therapeutic Market, By Region:
1. How big is the global Anti-VEGF Therapeutic market?
2. What is the demand of the global Anti-VEGF Therapeutic market?
3. What is the year over year growth of the global Anti-VEGF Therapeutic market?
4. What is the production and production value of the global Anti-VEGF Therapeutic market?
5. Who are the key producers in the global Anti-VEGF Therapeutic market?
6. What are the growth factors driving the market demand?
This report studies the global Anti-VEGF Therapeutic production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Anti-VEGF Therapeutic, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2021 as the base year. This report explores demand trends and competition, as well as details the characteristics of Anti-VEGF Therapeutic that contribute to its increasing demand across many markets.
The global Anti-VEGF Therapeutic market size is expected to reach $ million by 2028, rising at a market growth of % CAGR during the forecast period (2022-2028).
Highlights and key features of the study
Global Anti-VEGF Therapeutic total production and demand, 2017-2028, (K Units)
Global Anti-VEGF Therapeutic total production value, 2017-2028, (USD Million)
Global Anti-VEGF Therapeutic production by region & country, production, value, CAGR, 2017-2028, (USD Million) & (K Units)
Global Anti-VEGF Therapeutic consumption by region & country, CAGR, 2017-2028 & (K Units)
U.S. VS China: Anti-VEGF Therapeutic domestic production, consumption, key domestic manufacturers and share
Global Anti-VEGF Therapeutic production by manufacturer, production, price, value and market share 2017-2022, (USD Million) & (K Units)
Global Anti-VEGF Therapeutic production by Type, production, value, CAGR, 2017-2028, (USD Million) & (K Units)
Global Anti-VEGF Therapeutic production by Application production, value, CAGR, 2017-2028, (USD Million) & (K Units)
This reports profiles key players in the global Anti-VEGF Therapeutic market based on the following parameters – headquarters, production locations, products portfolio, Anti-VEGF Therapeutic revenue, sales, average price and gross margin, recent developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Anti-VEGF Therapeutic market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2017-2028 by year with 2021 as the base year, 2022 as the estimate year, and 2028 as the forecast year.
Global Anti-VEGF Therapeutic Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Aflibercept (Eylea)
- Ranibizumab (Lucentis)
- Brolucizumab (Beovu)
- Others
- Macular Edema
- Diabetic Retinopathy
- Retinal Vein Occlusion
- Age-related Macular Degeneration
- Others
- Regeneron Pharmaceuticals
- Bayer
- Novartis
- Roche
- Biogen
- Pfizer
- Coherus BioSciences
- Amgen
- Bausch Health Companies
- Viatris
1. How big is the global Anti-VEGF Therapeutic market?
2. What is the demand of the global Anti-VEGF Therapeutic market?
3. What is the year over year growth of the global Anti-VEGF Therapeutic market?
4. What is the production and production value of the global Anti-VEGF Therapeutic market?
5. Who are the key producers in the global Anti-VEGF Therapeutic market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Anti-VEGF Therapeutic Introduction
1.2 World Anti-VEGF Therapeutic Supply & Forecast
1.2.1 World Anti-VEGF Therapeutic Production Value (2017 & 2021 & 2028)
1.2.2 World Anti-VEGF Therapeutic Production (2017-2028)
1.2.3 World Anti-VEGF Therapeutic Pricing Trends (2017-2028)
1.3 World Anti-VEGF Therapeutic Production by Region
1.3.1 World Anti-VEGF Therapeutic Production Value by Region (2017-2028)
1.3.2 World Anti-VEGF Therapeutic Production by Region (2017-2028)
1.3.3 World Anti-VEGF Therapeutic Average Price by Region (2017-2028)
1.3.4 North America Anti-VEGF Therapeutic Production (2017-2028)
1.3.5 Europe Anti-VEGF Therapeutic Production (2017-2028)
1.3.6 China Anti-VEGF Therapeutic Production (2017-2028)
1.3.7 Japan Anti-VEGF Therapeutic Production (2017-2028)
1.4 Market Drivers, Restraints and Trends
1.4.1 Anti-VEGF Therapeutic Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Anti-VEGF Therapeutic Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Anti-VEGF Therapeutic Demand (2017-2028)
2.2 World Anti-VEGF Therapeutic Consumption by Region
2.2.1 World Anti-VEGF Therapeutic Consumption by Region (2017-2022)
2.2.2 World Anti-VEGF Therapeutic Consumption Forecast by Region (2023-2028)
2.3 United States Anti-VEGF Therapeutic Consumption (2017-2028)
2.4 China Anti-VEGF Therapeutic Consumption (2017-2028)
2.5 Europe Anti-VEGF Therapeutic Consumption (2017-2028)
2.6 Japan Anti-VEGF Therapeutic Consumption (2017-2028)
2.7 South Korea Anti-VEGF Therapeutic Consumption (2017-2028)
2.8 ASEAN Anti-VEGF Therapeutic Consumption (2017-2028)
2.9 India Anti-VEGF Therapeutic Consumption (2017-2028)
3 WORLD ANTI-VEGF THERAPEUTIC MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Anti-VEGF Therapeutic Production Value by Manufacturer (2017-2022)
3.2 World Anti-VEGF Therapeutic Production by Manufacturer (2017-2022)
3.3 World Anti-VEGF Therapeutic Average Price by Manufacturer (2017-2022)
3.4 Anti-VEGF Therapeutic Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Anti-VEGF Therapeutic Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Anti-VEGF Therapeutic in 2021
3.5.3 Global Concentration Ratios (CR8) for Anti-VEGF Therapeutic in 2021
3.6 Anti-VEGF Therapeutic Market: Overall Company Footprint Analysis
3.6.1 Anti-VEGF Therapeutic Market: Region Footprint
3.6.2 Anti-VEGF Therapeutic Market: Company Product Type Footprint
3.6.3 Anti-VEGF Therapeutic Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Anti-VEGF Therapeutic Production Value Comparison
4.1.1 United States VS China: Anti-VEGF Therapeutic Production Value Comparison (2017 & 2021 & 2028)
4.1.2 United States VS China: Anti-VEGF Therapeutic Production Value Market Share Comparison (2017 & 2021 & 2028)
4.2 United States VS China: Anti-VEGF Therapeutic Production Comparison
4.2.1 United States VS China: Anti-VEGF Therapeutic Production Comparison (2017 & 2021 & 2028)
4.2.2 United States VS China: Anti-VEGF Therapeutic Production Market Share Comparison (2017 & 2021 & 2028)
4.3 United States VS China: Anti-VEGF Therapeutic Consumption Comparison
4.3.1 United States VS China: Anti-VEGF Therapeutic Consumption Comparison (2017 & 2021 & 2028)
4.3.2 United States VS China: Anti-VEGF Therapeutic Consumption Market Share Comparison (2017 & 2021 & 2028)
4.4 United States Anti-VEGF Therapeutic Key Producers and Market Share, 2017-2022
4.4.1 Major Manufacturer of Anti-VEGF Therapeutic in United States, Company Headquarters and Production Place (States, Country)
4.4.2 United States Anti-VEGF Therapeutic Production Value by Domestic Manufacturer, (2017-2022)
4.4.3 United States Anti-VEGF Therapeutic Production by Domestic Manufacturer, (2017-2022)
4.5 China Anti-VEGF Therapeutic Key Producers and Market Share, 2017-2022
4.5.1 Major Manufacturer of Anti-VEGF Therapeutic in China, Company Headquarters and Production Place (Province, Country)
4.5.2 China Anti-VEGF Therapeutic Production Value by Domestic Manufacturer, (2017-2022)
4.5.3 China Anti-VEGF Therapeutic Production by Domestic Manufacturer, (2017-2022)
4.6 Rest of World Anti-VEGF Therapeutic Key Producers and Market Share, 2017-2022
4.6.1 Major Manufacturer of Anti-VEGF Therapeutic in Rest of World, Company Headquarters and Production Place (State, Country)
4.6.2 Rest of World Anti-VEGF Therapeutic Production Value by Domestic Manufacturer, (2017-2022)
4.6.3 Rest of World Anti-VEGF Therapeutic Production by Domestic Manufacturer, (2017-2022)
5 MARKET ANALYSIS BY TYPE
5.1 World Anti-VEGF Therapeutic Market Size Overview by Type: 2017 VS 2021 VS 2028
5.2 Segment Introduction by Type
5.2.1 Aflibercept (Eylea)
5.2.2 Ranibizumab (Lucentis)
5.2.3 Brolucizumab (Beovu)
5.2.4 Others
5.3 Market Segment by Type
5.3.1 World Anti-VEGF Therapeutic Production by Type (2017-2028)
5.3.2 World Anti-VEGF Therapeutic Production Value by Type (2017-2028)
5.3.3 World Anti-VEGF Therapeutic Average Price by Type (2017-2028)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Anti-VEGF Therapeutic Market Size Overview by Application: 2017 VS 2021 VS 2028
6.2 Segment Introduction by Application
6.2.1 Macular Edema
6.2.2 Diabetic Retinopathy
6.2.3 Retinal Vein Occlusion
6.2.4 Age-related Macular Degeneration
6.2.5 Others
6.3 Market Segment by Application
6.3.1 World Anti-VEGF Therapeutic Production by Application (2017-2028)
6.3.2 World Anti-VEGF Therapeutic Production Value by Application (2017-2028)
6.3.3 World Anti-VEGF Therapeutic Average Price by Application (2017-2028)
7 COMPANY PROFILES
7.1 Regeneron Pharmaceuticals
7.1.1 Regeneron Pharmaceuticals Details
7.1.2 Regeneron Pharmaceuticals Major Business
7.1.3 Regeneron Pharmaceuticals Anti-VEGF Therapeutic Product and Services
7.1.4 Regeneron Pharmaceuticals Anti-VEGF Therapeutic Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.1.5 Regeneron Pharmaceuticals Recent Developments/Updates
7.1.6 Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
7.2 Bayer
7.2.1 Bayer Details
7.2.2 Bayer Major Business
7.2.3 Bayer Anti-VEGF Therapeutic Product and Services
7.2.4 Bayer Anti-VEGF Therapeutic Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.2.5 Bayer Recent Developments/Updates
7.2.6 Bayer Competitive Strengths & Weaknesses
7.3 Novartis
7.3.1 Novartis Details
7.3.2 Novartis Major Business
7.3.3 Novartis Anti-VEGF Therapeutic Product and Services
7.3.4 Novartis Anti-VEGF Therapeutic Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.3.5 Novartis Recent Developments/Updates
7.3.6 Novartis Competitive Strengths & Weaknesses
7.4 Roche
7.4.1 Roche Details
7.4.2 Roche Major Business
7.4.3 Roche Anti-VEGF Therapeutic Product and Services
7.4.4 Roche Anti-VEGF Therapeutic Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.4.5 Roche Recent Developments/Updates
7.4.6 Roche Competitive Strengths & Weaknesses
7.5 Biogen
7.5.1 Biogen Details
7.5.2 Biogen Major Business
7.5.3 Biogen Anti-VEGF Therapeutic Product and Services
7.5.4 Biogen Anti-VEGF Therapeutic Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.5.5 Biogen Recent Developments/Updates
7.5.6 Biogen Competitive Strengths & Weaknesses
7.6 Pfizer
7.6.1 Pfizer Details
7.6.2 Pfizer Major Business
7.6.3 Pfizer Anti-VEGF Therapeutic Product and Services
7.6.4 Pfizer Anti-VEGF Therapeutic Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.6.5 Pfizer Recent Developments/Updates
7.6.6 Pfizer Competitive Strengths & Weaknesses
7.7 Coherus BioSciences
7.7.1 Coherus BioSciences Details
7.7.2 Coherus BioSciences Major Business
7.7.3 Coherus BioSciences Anti-VEGF Therapeutic Product and Services
7.7.4 Coherus BioSciences Anti-VEGF Therapeutic Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.7.5 Coherus BioSciences Recent Developments/Updates
7.7.6 Coherus BioSciences Competitive Strengths & Weaknesses
7.8 Amgen
7.8.1 Amgen Details
7.8.2 Amgen Major Business
7.8.3 Amgen Anti-VEGF Therapeutic Product and Services
7.8.4 Amgen Anti-VEGF Therapeutic Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.8.5 Amgen Recent Developments/Updates
7.8.6 Amgen Competitive Strengths & Weaknesses
7.9 Bausch Health Companies
7.9.1 Bausch Health Companies Details
7.9.2 Bausch Health Companies Major Business
7.9.3 Bausch Health Companies Anti-VEGF Therapeutic Product and Services
7.9.4 Bausch Health Companies Anti-VEGF Therapeutic Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.9.5 Bausch Health Companies Recent Developments/Updates
7.9.6 Bausch Health Companies Competitive Strengths & Weaknesses
7.10 Viatris
7.10.1 Viatris Details
7.10.2 Viatris Major Business
7.10.3 Viatris Anti-VEGF Therapeutic Product and Services
7.10.4 Viatris Anti-VEGF Therapeutic Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.10.5 Viatris Recent Developments/Updates
7.10.6 Viatris Competitive Strengths & Weaknesses
8 RAW MATERIAL AND INDUSTRY CHAIN
8.1 Raw Material of Anti-VEGF Therapeutic and Key Manufacturers
8.2 Anti-VEGF Therapeutic Manufacturing Costs
8.3 Anti-VEGF Therapeutic Production Process
8.4 Anti-VEGF Therapeutic Industrial Chain
9 DISTRIBUTION CHANNEL ANALYSIS
9.1 Distribution Channel Breakdown for Anti-VEGF Therapeutic Shipments (%): 2017-2028
9.1.1 Direct Channel
9.1.2 Indirect Channel
9.2 Anti-VEGF Therapeutic Typical Distributors
9.3 Anti-VEGF Therapeutic Typical Customers
10 RESEARCH FINDINGS AND CONCLUSION
11 APPENDIX
11.1 Methodology
11.2 Research Process and Data Source
11.3 Disclaimer
1.1 Anti-VEGF Therapeutic Introduction
1.2 World Anti-VEGF Therapeutic Supply & Forecast
1.2.1 World Anti-VEGF Therapeutic Production Value (2017 & 2021 & 2028)
1.2.2 World Anti-VEGF Therapeutic Production (2017-2028)
1.2.3 World Anti-VEGF Therapeutic Pricing Trends (2017-2028)
1.3 World Anti-VEGF Therapeutic Production by Region
1.3.1 World Anti-VEGF Therapeutic Production Value by Region (2017-2028)
1.3.2 World Anti-VEGF Therapeutic Production by Region (2017-2028)
1.3.3 World Anti-VEGF Therapeutic Average Price by Region (2017-2028)
1.3.4 North America Anti-VEGF Therapeutic Production (2017-2028)
1.3.5 Europe Anti-VEGF Therapeutic Production (2017-2028)
1.3.6 China Anti-VEGF Therapeutic Production (2017-2028)
1.3.7 Japan Anti-VEGF Therapeutic Production (2017-2028)
1.4 Market Drivers, Restraints and Trends
1.4.1 Anti-VEGF Therapeutic Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Anti-VEGF Therapeutic Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Anti-VEGF Therapeutic Demand (2017-2028)
2.2 World Anti-VEGF Therapeutic Consumption by Region
2.2.1 World Anti-VEGF Therapeutic Consumption by Region (2017-2022)
2.2.2 World Anti-VEGF Therapeutic Consumption Forecast by Region (2023-2028)
2.3 United States Anti-VEGF Therapeutic Consumption (2017-2028)
2.4 China Anti-VEGF Therapeutic Consumption (2017-2028)
2.5 Europe Anti-VEGF Therapeutic Consumption (2017-2028)
2.6 Japan Anti-VEGF Therapeutic Consumption (2017-2028)
2.7 South Korea Anti-VEGF Therapeutic Consumption (2017-2028)
2.8 ASEAN Anti-VEGF Therapeutic Consumption (2017-2028)
2.9 India Anti-VEGF Therapeutic Consumption (2017-2028)
3 WORLD ANTI-VEGF THERAPEUTIC MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Anti-VEGF Therapeutic Production Value by Manufacturer (2017-2022)
3.2 World Anti-VEGF Therapeutic Production by Manufacturer (2017-2022)
3.3 World Anti-VEGF Therapeutic Average Price by Manufacturer (2017-2022)
3.4 Anti-VEGF Therapeutic Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Anti-VEGF Therapeutic Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Anti-VEGF Therapeutic in 2021
3.5.3 Global Concentration Ratios (CR8) for Anti-VEGF Therapeutic in 2021
3.6 Anti-VEGF Therapeutic Market: Overall Company Footprint Analysis
3.6.1 Anti-VEGF Therapeutic Market: Region Footprint
3.6.2 Anti-VEGF Therapeutic Market: Company Product Type Footprint
3.6.3 Anti-VEGF Therapeutic Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Anti-VEGF Therapeutic Production Value Comparison
4.1.1 United States VS China: Anti-VEGF Therapeutic Production Value Comparison (2017 & 2021 & 2028)
4.1.2 United States VS China: Anti-VEGF Therapeutic Production Value Market Share Comparison (2017 & 2021 & 2028)
4.2 United States VS China: Anti-VEGF Therapeutic Production Comparison
4.2.1 United States VS China: Anti-VEGF Therapeutic Production Comparison (2017 & 2021 & 2028)
4.2.2 United States VS China: Anti-VEGF Therapeutic Production Market Share Comparison (2017 & 2021 & 2028)
4.3 United States VS China: Anti-VEGF Therapeutic Consumption Comparison
4.3.1 United States VS China: Anti-VEGF Therapeutic Consumption Comparison (2017 & 2021 & 2028)
4.3.2 United States VS China: Anti-VEGF Therapeutic Consumption Market Share Comparison (2017 & 2021 & 2028)
4.4 United States Anti-VEGF Therapeutic Key Producers and Market Share, 2017-2022
4.4.1 Major Manufacturer of Anti-VEGF Therapeutic in United States, Company Headquarters and Production Place (States, Country)
4.4.2 United States Anti-VEGF Therapeutic Production Value by Domestic Manufacturer, (2017-2022)
4.4.3 United States Anti-VEGF Therapeutic Production by Domestic Manufacturer, (2017-2022)
4.5 China Anti-VEGF Therapeutic Key Producers and Market Share, 2017-2022
4.5.1 Major Manufacturer of Anti-VEGF Therapeutic in China, Company Headquarters and Production Place (Province, Country)
4.5.2 China Anti-VEGF Therapeutic Production Value by Domestic Manufacturer, (2017-2022)
4.5.3 China Anti-VEGF Therapeutic Production by Domestic Manufacturer, (2017-2022)
4.6 Rest of World Anti-VEGF Therapeutic Key Producers and Market Share, 2017-2022
4.6.1 Major Manufacturer of Anti-VEGF Therapeutic in Rest of World, Company Headquarters and Production Place (State, Country)
4.6.2 Rest of World Anti-VEGF Therapeutic Production Value by Domestic Manufacturer, (2017-2022)
4.6.3 Rest of World Anti-VEGF Therapeutic Production by Domestic Manufacturer, (2017-2022)
5 MARKET ANALYSIS BY TYPE
5.1 World Anti-VEGF Therapeutic Market Size Overview by Type: 2017 VS 2021 VS 2028
5.2 Segment Introduction by Type
5.2.1 Aflibercept (Eylea)
5.2.2 Ranibizumab (Lucentis)
5.2.3 Brolucizumab (Beovu)
5.2.4 Others
5.3 Market Segment by Type
5.3.1 World Anti-VEGF Therapeutic Production by Type (2017-2028)
5.3.2 World Anti-VEGF Therapeutic Production Value by Type (2017-2028)
5.3.3 World Anti-VEGF Therapeutic Average Price by Type (2017-2028)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Anti-VEGF Therapeutic Market Size Overview by Application: 2017 VS 2021 VS 2028
6.2 Segment Introduction by Application
6.2.1 Macular Edema
6.2.2 Diabetic Retinopathy
6.2.3 Retinal Vein Occlusion
6.2.4 Age-related Macular Degeneration
6.2.5 Others
6.3 Market Segment by Application
6.3.1 World Anti-VEGF Therapeutic Production by Application (2017-2028)
6.3.2 World Anti-VEGF Therapeutic Production Value by Application (2017-2028)
6.3.3 World Anti-VEGF Therapeutic Average Price by Application (2017-2028)
7 COMPANY PROFILES
7.1 Regeneron Pharmaceuticals
7.1.1 Regeneron Pharmaceuticals Details
7.1.2 Regeneron Pharmaceuticals Major Business
7.1.3 Regeneron Pharmaceuticals Anti-VEGF Therapeutic Product and Services
7.1.4 Regeneron Pharmaceuticals Anti-VEGF Therapeutic Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.1.5 Regeneron Pharmaceuticals Recent Developments/Updates
7.1.6 Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
7.2 Bayer
7.2.1 Bayer Details
7.2.2 Bayer Major Business
7.2.3 Bayer Anti-VEGF Therapeutic Product and Services
7.2.4 Bayer Anti-VEGF Therapeutic Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.2.5 Bayer Recent Developments/Updates
7.2.6 Bayer Competitive Strengths & Weaknesses
7.3 Novartis
7.3.1 Novartis Details
7.3.2 Novartis Major Business
7.3.3 Novartis Anti-VEGF Therapeutic Product and Services
7.3.4 Novartis Anti-VEGF Therapeutic Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.3.5 Novartis Recent Developments/Updates
7.3.6 Novartis Competitive Strengths & Weaknesses
7.4 Roche
7.4.1 Roche Details
7.4.2 Roche Major Business
7.4.3 Roche Anti-VEGF Therapeutic Product and Services
7.4.4 Roche Anti-VEGF Therapeutic Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.4.5 Roche Recent Developments/Updates
7.4.6 Roche Competitive Strengths & Weaknesses
7.5 Biogen
7.5.1 Biogen Details
7.5.2 Biogen Major Business
7.5.3 Biogen Anti-VEGF Therapeutic Product and Services
7.5.4 Biogen Anti-VEGF Therapeutic Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.5.5 Biogen Recent Developments/Updates
7.5.6 Biogen Competitive Strengths & Weaknesses
7.6 Pfizer
7.6.1 Pfizer Details
7.6.2 Pfizer Major Business
7.6.3 Pfizer Anti-VEGF Therapeutic Product and Services
7.6.4 Pfizer Anti-VEGF Therapeutic Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.6.5 Pfizer Recent Developments/Updates
7.6.6 Pfizer Competitive Strengths & Weaknesses
7.7 Coherus BioSciences
7.7.1 Coherus BioSciences Details
7.7.2 Coherus BioSciences Major Business
7.7.3 Coherus BioSciences Anti-VEGF Therapeutic Product and Services
7.7.4 Coherus BioSciences Anti-VEGF Therapeutic Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.7.5 Coherus BioSciences Recent Developments/Updates
7.7.6 Coherus BioSciences Competitive Strengths & Weaknesses
7.8 Amgen
7.8.1 Amgen Details
7.8.2 Amgen Major Business
7.8.3 Amgen Anti-VEGF Therapeutic Product and Services
7.8.4 Amgen Anti-VEGF Therapeutic Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.8.5 Amgen Recent Developments/Updates
7.8.6 Amgen Competitive Strengths & Weaknesses
7.9 Bausch Health Companies
7.9.1 Bausch Health Companies Details
7.9.2 Bausch Health Companies Major Business
7.9.3 Bausch Health Companies Anti-VEGF Therapeutic Product and Services
7.9.4 Bausch Health Companies Anti-VEGF Therapeutic Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.9.5 Bausch Health Companies Recent Developments/Updates
7.9.6 Bausch Health Companies Competitive Strengths & Weaknesses
7.10 Viatris
7.10.1 Viatris Details
7.10.2 Viatris Major Business
7.10.3 Viatris Anti-VEGF Therapeutic Product and Services
7.10.4 Viatris Anti-VEGF Therapeutic Production, Price, Value, Gross Margin and Market Share (2017-2022)
7.10.5 Viatris Recent Developments/Updates
7.10.6 Viatris Competitive Strengths & Weaknesses
8 RAW MATERIAL AND INDUSTRY CHAIN
8.1 Raw Material of Anti-VEGF Therapeutic and Key Manufacturers
8.2 Anti-VEGF Therapeutic Manufacturing Costs
8.3 Anti-VEGF Therapeutic Production Process
8.4 Anti-VEGF Therapeutic Industrial Chain
9 DISTRIBUTION CHANNEL ANALYSIS
9.1 Distribution Channel Breakdown for Anti-VEGF Therapeutic Shipments (%): 2017-2028
9.1.1 Direct Channel
9.1.2 Indirect Channel
9.2 Anti-VEGF Therapeutic Typical Distributors
9.3 Anti-VEGF Therapeutic Typical Customers
10 RESEARCH FINDINGS AND CONCLUSION
11 APPENDIX
11.1 Methodology
11.2 Research Process and Data Source
11.3 Disclaimer
LIST OF TABLES
Table 1. World Anti-VEGF Therapeutic Production Value by Region (2017, 2022 and 2028) & (USD Million)
Table 2. World Anti-VEGF Therapeutic Production Value by Region (2017-2022) & (USD Million)
Table 3. World Anti-VEGF Therapeutic Production Value by Region (2023-2028) & (USD Million)
Table 4. World Anti-VEGF Therapeutic Production Value Market Share by Region (2017-2022)
Table 5. World Anti-VEGF Therapeutic Production Value Market Share by Region (2023-2028)
Table 6. World Anti-VEGF Therapeutic Production by Region (2017-2022) & (K Units)
Table 7. World Anti-VEGF Therapeutic Production by Region (2023-2028) & (K Units)
Table 8. World Anti-VEGF Therapeutic Production Market Share by Region (2017-2022)
Table 9. World Anti-VEGF Therapeutic Production Market Share by Region (2023-2028)
Table 10. World Anti-VEGF Therapeutic Average Price by Region (2017-2022) & (US$/Unit)
Table 11. World Anti-VEGF Therapeutic Average Price by Region (2023-2028) & (US$/Unit)
Table 12. Anti-VEGF Therapeutic Major Market Trends
Table 13. World Anti-VEGF Therapeutic Consumption Growth Rate Forecast by Region (2017 & 2021 & 2028) & (K Units)
Table 14. World Anti-VEGF Therapeutic Consumption by Region (2017-2022) & (K Units)
Table 15. World Anti-VEGF Therapeutic Consumption Forecast by Region (2023-2028) & (K Units)
Table 16. World Anti-VEGF Therapeutic Production Value by Manufacturer (2017-2022) & (USD Million)
Table 17. Production Value Market Share of Key Anti-VEGF Therapeutic Producers in 2021
Table 18. World Anti-VEGF Therapeutic Production by Manufacturer (2017-2022) & (K Units)
Table 19. Production Market Share of Key Anti-VEGF Therapeutic Producers in 2021
Table 20. World Anti-VEGF Therapeutic Average Price by Manufacturer (2017-2022) & (US$/Unit)
Table 21. Global Anti-VEGF Therapeutic Company Evaluation Quadrant
Table 22. World Anti-VEGF Therapeutic Industry Rank of Major Manufacturers, Based on Production Value in 2021
Table 23. Head Office and Anti-VEGF Therapeutic Production Site of Key Manufacturer
Table 24. Anti-VEGF Therapeutic Market: Company Product Type Footprint
Table 25. Anti-VEGF Therapeutic Market: Company Product Application Footprint
Table 26. Anti-VEGF Therapeutic Competitive Factors
Table 27. Anti-VEGF Therapeutic New Entrant and Capacity Expansion Plans
Table 28. Anti-VEGF Therapeutic Mergers & Acquisitions Activity
Table 29. United States VS China Anti-VEGF Therapeutic Production Value Comparison, (2017 & 2021 & 2028) & (USD Million)
Table 30. United States VS China Anti-VEGF Therapeutic Production Comparison, (2017 & 2021 & 2028) & (K Units)
Table 31. United States VS China Anti-VEGF Therapeutic Consumption Comparison, (2017 & 2021 & 2028) & (K Units)
Table 32. Major Manufacturer of Anti-VEGF Therapeutic in United States, Company Headquarters and Production Place (States, Country)
Table 33. United States Anti-VEGF Therapeutic Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 34. United States Anti-VEGF Therapeutic Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 35. United States Anti-VEGF Therapeutic Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 36. United States Anti-VEGF Therapeutic Production Market Share by Domestic Manufacturer, (2017-2022)
Table 37. Major Manufacturer of Anti-VEGF Therapeutic in China, Company Headquarters and Production Place (Province, Country)
Table 38. China Anti-VEGF Therapeutic Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 39. China Anti-VEGF Therapeutic Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 40. China Anti-VEGF Therapeutic Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 41. China Anti-VEGF Therapeutic Production Market Share by Domestic Manufacturer, (2017-2022)
Table 42. Major Manufacturer of Anti-VEGF Therapeutic in Rest of World, Company Headquarters and Production Place (State, Country)
Table 43. Rest of World Anti-VEGF Therapeutic Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 44. Rest of World Anti-VEGF Therapeutic Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 45. Rest of World Anti-VEGF Therapeutic Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 46. Rest of World Anti-VEGF Therapeutic Production Market Share by Domestic Manufacturer, (2017-2022)
Table 47. World Anti-VEGF Therapeutic Production Value by Type, (USD Million), 2017 & 2021 & 2028
Table 48. World Anti-VEGF Therapeutic Production by Type (2017-2022) & (K Units)
Table 49. World Anti-VEGF Therapeutic Production by Type (2023-2028) & (K Units)
Table 50. World Anti-VEGF Therapeutic Production Value by Type (2017-2022) & (USD Million)
Table 51. World Anti-VEGF Therapeutic Production Value by Type (2023-2028) & (USD Million)
Table 52. World Anti-VEGF Therapeutic Average Price by Type (2017-2022) & (US$/Unit)
Table 53. World Anti-VEGF Therapeutic Average Price by Type (2023-2028) & (US$/Unit)
Table 54. World Anti-VEGF Therapeutic Production Value by Application, (USD Million), 2017 & 2021 & 2028
Table 55. World Anti-VEGF Therapeutic Production by Application (2017-2022) & (K Units)
Table 56. World Anti-VEGF Therapeutic Production by Application (2023-2028) & (K Units)
Table 57. World Anti-VEGF Therapeutic Production Value by Application (2017-2022) & (USD Million)
Table 58. World Anti-VEGF Therapeutic Production Value by Application (2023-2028) & (USD Million)
Table 59. World Anti-VEGF Therapeutic Average Price by Application (2017-2022) & (US$/Unit)
Table 60. World Anti-VEGF Therapeutic Average Price by Application (2023-2028) & (US$/Unit)
Table 61. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 62. Regeneron Pharmaceuticals Major Business
Table 63. Regeneron Pharmaceuticals Anti-VEGF Therapeutic Product and Services
Table 64. Regeneron Pharmaceuticals Anti-VEGF Therapeutic Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 65. Regeneron Pharmaceuticals Recent Developments/Updates
Table 66. Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
Table 67. Bayer Basic Information, Manufacturing Base and Competitors
Table 68. Bayer Major Business
Table 69. Bayer Anti-VEGF Therapeutic Product and Services
Table 70. Bayer Anti-VEGF Therapeutic Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 71. Bayer Recent Developments/Updates
Table 72. Bayer Competitive Strengths & Weaknesses
Table 73. Novartis Basic Information, Manufacturing Base and Competitors
Table 74. Novartis Major Business
Table 75. Novartis Anti-VEGF Therapeutic Product and Services
Table 76. Novartis Anti-VEGF Therapeutic Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 77. Novartis Recent Developments/Updates
Table 78. Novartis Competitive Strengths & Weaknesses
Table 79. Roche Basic Information, Manufacturing Base and Competitors
Table 80. Roche Major Business
Table 81. Roche Anti-VEGF Therapeutic Product and Services
Table 82. Roche Anti-VEGF Therapeutic Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 83. Roche Recent Developments/Updates
Table 84. Roche Competitive Strengths & Weaknesses
Table 85. Biogen Basic Information, Manufacturing Base and Competitors
Table 86. Biogen Major Business
Table 87. Biogen Anti-VEGF Therapeutic Product and Services
Table 88. Biogen Anti-VEGF Therapeutic Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 89. Biogen Recent Developments/Updates
Table 90. Biogen Competitive Strengths & Weaknesses
Table 91. Pfizer Basic Information, Manufacturing Base and Competitors
Table 92. Pfizer Major Business
Table 93. Pfizer Anti-VEGF Therapeutic Product and Services
Table 94. Pfizer Anti-VEGF Therapeutic Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 95. Pfizer Recent Developments/Updates
Table 96. Pfizer Competitive Strengths & Weaknesses
Table 97. Coherus BioSciences Basic Information, Manufacturing Base and Competitors
Table 98. Coherus BioSciences Major Business
Table 99. Coherus BioSciences Anti-VEGF Therapeutic Product and Services
Table 100. Coherus BioSciences Anti-VEGF Therapeutic Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 101. Coherus BioSciences Recent Developments/Updates
Table 102. Coherus BioSciences Competitive Strengths & Weaknesses
Table 103. Amgen Basic Information, Manufacturing Base and Competitors
Table 104. Amgen Major Business
Table 105. Amgen Anti-VEGF Therapeutic Product and Services
Table 106. Amgen Anti-VEGF Therapeutic Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 107. Amgen Recent Developments/Updates
Table 108. Amgen Competitive Strengths & Weaknesses
Table 109. Bausch Health Companies Basic Information, Manufacturing Base and Competitors
Table 110. Bausch Health Companies Major Business
Table 111. Bausch Health Companies Anti-VEGF Therapeutic Product and Services
Table 112. Bausch Health Companies Anti-VEGF Therapeutic Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 113. Bausch Health Companies Recent Developments/Updates
Table 114. Viatris Basic Information, Manufacturing Base and Competitors
Table 115. Viatris Major Business
Table 116. Viatris Anti-VEGF Therapeutic Product and Services
Table 117. Viatris Anti-VEGF Therapeutic Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 118. Anti-VEGF Therapeutic Raw Material
Table 119. Key Manufacturers of Anti-VEGF Therapeutic Raw Materials
Table 120. Anti-VEGF Therapeutic Typical Distributors
Table 121. Anti-VEGF Therapeutic Typical Customers
Table 1. World Anti-VEGF Therapeutic Production Value by Region (2017, 2022 and 2028) & (USD Million)
Table 2. World Anti-VEGF Therapeutic Production Value by Region (2017-2022) & (USD Million)
Table 3. World Anti-VEGF Therapeutic Production Value by Region (2023-2028) & (USD Million)
Table 4. World Anti-VEGF Therapeutic Production Value Market Share by Region (2017-2022)
Table 5. World Anti-VEGF Therapeutic Production Value Market Share by Region (2023-2028)
Table 6. World Anti-VEGF Therapeutic Production by Region (2017-2022) & (K Units)
Table 7. World Anti-VEGF Therapeutic Production by Region (2023-2028) & (K Units)
Table 8. World Anti-VEGF Therapeutic Production Market Share by Region (2017-2022)
Table 9. World Anti-VEGF Therapeutic Production Market Share by Region (2023-2028)
Table 10. World Anti-VEGF Therapeutic Average Price by Region (2017-2022) & (US$/Unit)
Table 11. World Anti-VEGF Therapeutic Average Price by Region (2023-2028) & (US$/Unit)
Table 12. Anti-VEGF Therapeutic Major Market Trends
Table 13. World Anti-VEGF Therapeutic Consumption Growth Rate Forecast by Region (2017 & 2021 & 2028) & (K Units)
Table 14. World Anti-VEGF Therapeutic Consumption by Region (2017-2022) & (K Units)
Table 15. World Anti-VEGF Therapeutic Consumption Forecast by Region (2023-2028) & (K Units)
Table 16. World Anti-VEGF Therapeutic Production Value by Manufacturer (2017-2022) & (USD Million)
Table 17. Production Value Market Share of Key Anti-VEGF Therapeutic Producers in 2021
Table 18. World Anti-VEGF Therapeutic Production by Manufacturer (2017-2022) & (K Units)
Table 19. Production Market Share of Key Anti-VEGF Therapeutic Producers in 2021
Table 20. World Anti-VEGF Therapeutic Average Price by Manufacturer (2017-2022) & (US$/Unit)
Table 21. Global Anti-VEGF Therapeutic Company Evaluation Quadrant
Table 22. World Anti-VEGF Therapeutic Industry Rank of Major Manufacturers, Based on Production Value in 2021
Table 23. Head Office and Anti-VEGF Therapeutic Production Site of Key Manufacturer
Table 24. Anti-VEGF Therapeutic Market: Company Product Type Footprint
Table 25. Anti-VEGF Therapeutic Market: Company Product Application Footprint
Table 26. Anti-VEGF Therapeutic Competitive Factors
Table 27. Anti-VEGF Therapeutic New Entrant and Capacity Expansion Plans
Table 28. Anti-VEGF Therapeutic Mergers & Acquisitions Activity
Table 29. United States VS China Anti-VEGF Therapeutic Production Value Comparison, (2017 & 2021 & 2028) & (USD Million)
Table 30. United States VS China Anti-VEGF Therapeutic Production Comparison, (2017 & 2021 & 2028) & (K Units)
Table 31. United States VS China Anti-VEGF Therapeutic Consumption Comparison, (2017 & 2021 & 2028) & (K Units)
Table 32. Major Manufacturer of Anti-VEGF Therapeutic in United States, Company Headquarters and Production Place (States, Country)
Table 33. United States Anti-VEGF Therapeutic Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 34. United States Anti-VEGF Therapeutic Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 35. United States Anti-VEGF Therapeutic Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 36. United States Anti-VEGF Therapeutic Production Market Share by Domestic Manufacturer, (2017-2022)
Table 37. Major Manufacturer of Anti-VEGF Therapeutic in China, Company Headquarters and Production Place (Province, Country)
Table 38. China Anti-VEGF Therapeutic Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 39. China Anti-VEGF Therapeutic Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 40. China Anti-VEGF Therapeutic Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 41. China Anti-VEGF Therapeutic Production Market Share by Domestic Manufacturer, (2017-2022)
Table 42. Major Manufacturer of Anti-VEGF Therapeutic in Rest of World, Company Headquarters and Production Place (State, Country)
Table 43. Rest of World Anti-VEGF Therapeutic Production Value by Domestic Manufacturer, (2017-2022) & (USD Million)
Table 44. Rest of World Anti-VEGF Therapeutic Production Value Market Share by Domestic Manufacturer, (2017-2022)
Table 45. Rest of World Anti-VEGF Therapeutic Production by Domestic Manufacturer, (2017-2022) & (K Units)
Table 46. Rest of World Anti-VEGF Therapeutic Production Market Share by Domestic Manufacturer, (2017-2022)
Table 47. World Anti-VEGF Therapeutic Production Value by Type, (USD Million), 2017 & 2021 & 2028
Table 48. World Anti-VEGF Therapeutic Production by Type (2017-2022) & (K Units)
Table 49. World Anti-VEGF Therapeutic Production by Type (2023-2028) & (K Units)
Table 50. World Anti-VEGF Therapeutic Production Value by Type (2017-2022) & (USD Million)
Table 51. World Anti-VEGF Therapeutic Production Value by Type (2023-2028) & (USD Million)
Table 52. World Anti-VEGF Therapeutic Average Price by Type (2017-2022) & (US$/Unit)
Table 53. World Anti-VEGF Therapeutic Average Price by Type (2023-2028) & (US$/Unit)
Table 54. World Anti-VEGF Therapeutic Production Value by Application, (USD Million), 2017 & 2021 & 2028
Table 55. World Anti-VEGF Therapeutic Production by Application (2017-2022) & (K Units)
Table 56. World Anti-VEGF Therapeutic Production by Application (2023-2028) & (K Units)
Table 57. World Anti-VEGF Therapeutic Production Value by Application (2017-2022) & (USD Million)
Table 58. World Anti-VEGF Therapeutic Production Value by Application (2023-2028) & (USD Million)
Table 59. World Anti-VEGF Therapeutic Average Price by Application (2017-2022) & (US$/Unit)
Table 60. World Anti-VEGF Therapeutic Average Price by Application (2023-2028) & (US$/Unit)
Table 61. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 62. Regeneron Pharmaceuticals Major Business
Table 63. Regeneron Pharmaceuticals Anti-VEGF Therapeutic Product and Services
Table 64. Regeneron Pharmaceuticals Anti-VEGF Therapeutic Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 65. Regeneron Pharmaceuticals Recent Developments/Updates
Table 66. Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
Table 67. Bayer Basic Information, Manufacturing Base and Competitors
Table 68. Bayer Major Business
Table 69. Bayer Anti-VEGF Therapeutic Product and Services
Table 70. Bayer Anti-VEGF Therapeutic Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 71. Bayer Recent Developments/Updates
Table 72. Bayer Competitive Strengths & Weaknesses
Table 73. Novartis Basic Information, Manufacturing Base and Competitors
Table 74. Novartis Major Business
Table 75. Novartis Anti-VEGF Therapeutic Product and Services
Table 76. Novartis Anti-VEGF Therapeutic Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 77. Novartis Recent Developments/Updates
Table 78. Novartis Competitive Strengths & Weaknesses
Table 79. Roche Basic Information, Manufacturing Base and Competitors
Table 80. Roche Major Business
Table 81. Roche Anti-VEGF Therapeutic Product and Services
Table 82. Roche Anti-VEGF Therapeutic Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 83. Roche Recent Developments/Updates
Table 84. Roche Competitive Strengths & Weaknesses
Table 85. Biogen Basic Information, Manufacturing Base and Competitors
Table 86. Biogen Major Business
Table 87. Biogen Anti-VEGF Therapeutic Product and Services
Table 88. Biogen Anti-VEGF Therapeutic Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 89. Biogen Recent Developments/Updates
Table 90. Biogen Competitive Strengths & Weaknesses
Table 91. Pfizer Basic Information, Manufacturing Base and Competitors
Table 92. Pfizer Major Business
Table 93. Pfizer Anti-VEGF Therapeutic Product and Services
Table 94. Pfizer Anti-VEGF Therapeutic Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 95. Pfizer Recent Developments/Updates
Table 96. Pfizer Competitive Strengths & Weaknesses
Table 97. Coherus BioSciences Basic Information, Manufacturing Base and Competitors
Table 98. Coherus BioSciences Major Business
Table 99. Coherus BioSciences Anti-VEGF Therapeutic Product and Services
Table 100. Coherus BioSciences Anti-VEGF Therapeutic Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 101. Coherus BioSciences Recent Developments/Updates
Table 102. Coherus BioSciences Competitive Strengths & Weaknesses
Table 103. Amgen Basic Information, Manufacturing Base and Competitors
Table 104. Amgen Major Business
Table 105. Amgen Anti-VEGF Therapeutic Product and Services
Table 106. Amgen Anti-VEGF Therapeutic Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 107. Amgen Recent Developments/Updates
Table 108. Amgen Competitive Strengths & Weaknesses
Table 109. Bausch Health Companies Basic Information, Manufacturing Base and Competitors
Table 110. Bausch Health Companies Major Business
Table 111. Bausch Health Companies Anti-VEGF Therapeutic Product and Services
Table 112. Bausch Health Companies Anti-VEGF Therapeutic Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 113. Bausch Health Companies Recent Developments/Updates
Table 114. Viatris Basic Information, Manufacturing Base and Competitors
Table 115. Viatris Major Business
Table 116. Viatris Anti-VEGF Therapeutic Product and Services
Table 117. Viatris Anti-VEGF Therapeutic Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2017-2022)
Table 118. Anti-VEGF Therapeutic Raw Material
Table 119. Key Manufacturers of Anti-VEGF Therapeutic Raw Materials
Table 120. Anti-VEGF Therapeutic Typical Distributors
Table 121. Anti-VEGF Therapeutic Typical Customers
LIST OF FIGURES
Figure 1. Anti-VEGF Therapeutic Picture
Figure 2. World Anti-VEGF Therapeutic Production Value: 2017 & 2021 & 2028, (USD Million)
Figure 3. World Anti-VEGF Therapeutic Production Value and Forecast (2017-2028) & (USD Million)
Figure 4. World Anti-VEGF Therapeutic Production (2017-2028) & (K Units)
Figure 5. World Anti-VEGF Therapeutic Average Price (2017-2028) & (US$/Unit)
Figure 6. World Anti-VEGF Therapeutic Production Value Market Share by Region (2017-2028)
Figure 7. World Anti-VEGF Therapeutic Production Market Share by Region (2017-2028)
Figure 8. North America Anti-VEGF Therapeutic Production (2017-2028) & (K Units)
Figure 9. Europe Anti-VEGF Therapeutic Production (2017-2028) & (K Units)
Figure 10. China Anti-VEGF Therapeutic Production (2017-2028) & (K Units)
Figure 11. Japan Anti-VEGF Therapeutic Production (2017-2028) & (K Units)
Figure 12. Anti-VEGF Therapeutic Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Anti-VEGF Therapeutic Demand (2017-2028) & (K Units)
Figure 15. World Anti-VEGF Therapeutic Consumption Market Share by Region (2017-2028)
Figure 16. United States Anti-VEGF Therapeutic Consumption (2017-2028) & (K Units)
Figure 17. China Anti-VEGF Therapeutic Consumption (2017-2028) & (K Units)
Figure 18. Europe Anti-VEGF Therapeutic Consumption (2017-2028) & (K Units)
Figure 19. Japan Anti-VEGF Therapeutic Consumption (2017-2028) & (K Units)
Figure 20. South Korea Anti-VEGF Therapeutic Consumption (2017-2028) & (K Units)
Figure 21. ASEAN Anti-VEGF Therapeutic Consumption (2017-2028) & (K Units)
Figure 22. India Anti-VEGF Therapeutic Consumption (2017-2028) & (K Units)
Figure 23. Producer Shipments of Anti-VEGF Therapeutic by Manufacturer Revenue ($MM) and Market Share (%): 2021
Figure 24. Global Four-firm Concentration Ratios (CR4) for Anti-VEGF Therapeutic Markets in 2021
Figure 25. Global Four-firm Concentration Ratios (CR8) for Anti-VEGF Therapeutic Markets in 2021
Figure 26. United States VS China: Anti-VEGF Therapeutic Production Value Market Share Comparison (2017 & 2021 & 2028)
Figure 27. United States VS China: Anti-VEGF Therapeutic Production Market Share Comparison (2017 & 2021 & 2028)
Figure 28. United States VS China: Anti-VEGF Therapeutic Consumption Market Share Comparison (2017 & 2021 & 2028)
Figure 29. Key Producers and Market Share of Anti-VEGF Therapeutic in United States
Figure 30. Key Producers and Market Share of Anti-VEGF Therapeutic in China
Figure 31. Key Producers and Market Share of Anti-VEGF Therapeutic in Rest of World
Figure 32. World Anti-VEGF Therapeutic Production Value by Type, (USD Million), 2017 & 2021 & 2028
Figure 33. World Anti-VEGF Therapeutic Production Value Market Share by Type in 2021
Figure 34. Aflibercept (Eylea)
Figure 35. Ranibizumab (Lucentis)
Figure 36. Brolucizumab (Beovu)
Figure 37. Others
Figure 38. World Anti-VEGF Therapeutic Production Market Share by Type (2017-2028)
Figure 39. World Anti-VEGF Therapeutic Production Value Market Share by Type (2017-2028)
Figure 40. World Anti-VEGF Therapeutic Average Price by Type (2017-2028) & (US$/Unit)
Figure 41. World Anti-VEGF Therapeutic Production Value by Application, (USD Million), 2017 & 2021 & 2028
Figure 42. World Anti-VEGF Therapeutic Production Value Market Share by Application in 2021
Figure 43. Macular Edema
Figure 44. Diabetic Retinopathy
Figure 45. Retinal Vein Occlusion
Figure 46. Age-related Macular Degeneration
Figure 47. Others
Figure 48. World Anti-VEGF Therapeutic Production Market Share by Application (2017-2028)
Figure 49. World Anti-VEGF Therapeutic Production Value Market Share by Application (2017-2028)
Figure 50. World Anti-VEGF Therapeutic Average Price by Application (2017-2028) & (US$/Unit)
Figure 51. Manufacturing Cost Structure Analysis of Anti-VEGF Therapeutic in 2021
Figure 52. Manufacturing Process Analysis of Anti-VEGF Therapeutic
Figure 53. Anti-VEGF Therapeutic Industrial Chain
Figure 54. Distribution Channel Breakdown for Anti-VEGF Therapeutic Shipments (%): 2017-2028
Figure 55. Direct Channel Pros & Cons
Figure 56. Indirect Channel Pros & Cons
Figure 57. Methodology
Figure 58. Research Process and Data Source
Figure 1. Anti-VEGF Therapeutic Picture
Figure 2. World Anti-VEGF Therapeutic Production Value: 2017 & 2021 & 2028, (USD Million)
Figure 3. World Anti-VEGF Therapeutic Production Value and Forecast (2017-2028) & (USD Million)
Figure 4. World Anti-VEGF Therapeutic Production (2017-2028) & (K Units)
Figure 5. World Anti-VEGF Therapeutic Average Price (2017-2028) & (US$/Unit)
Figure 6. World Anti-VEGF Therapeutic Production Value Market Share by Region (2017-2028)
Figure 7. World Anti-VEGF Therapeutic Production Market Share by Region (2017-2028)
Figure 8. North America Anti-VEGF Therapeutic Production (2017-2028) & (K Units)
Figure 9. Europe Anti-VEGF Therapeutic Production (2017-2028) & (K Units)
Figure 10. China Anti-VEGF Therapeutic Production (2017-2028) & (K Units)
Figure 11. Japan Anti-VEGF Therapeutic Production (2017-2028) & (K Units)
Figure 12. Anti-VEGF Therapeutic Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Anti-VEGF Therapeutic Demand (2017-2028) & (K Units)
Figure 15. World Anti-VEGF Therapeutic Consumption Market Share by Region (2017-2028)
Figure 16. United States Anti-VEGF Therapeutic Consumption (2017-2028) & (K Units)
Figure 17. China Anti-VEGF Therapeutic Consumption (2017-2028) & (K Units)
Figure 18. Europe Anti-VEGF Therapeutic Consumption (2017-2028) & (K Units)
Figure 19. Japan Anti-VEGF Therapeutic Consumption (2017-2028) & (K Units)
Figure 20. South Korea Anti-VEGF Therapeutic Consumption (2017-2028) & (K Units)
Figure 21. ASEAN Anti-VEGF Therapeutic Consumption (2017-2028) & (K Units)
Figure 22. India Anti-VEGF Therapeutic Consumption (2017-2028) & (K Units)
Figure 23. Producer Shipments of Anti-VEGF Therapeutic by Manufacturer Revenue ($MM) and Market Share (%): 2021
Figure 24. Global Four-firm Concentration Ratios (CR4) for Anti-VEGF Therapeutic Markets in 2021
Figure 25. Global Four-firm Concentration Ratios (CR8) for Anti-VEGF Therapeutic Markets in 2021
Figure 26. United States VS China: Anti-VEGF Therapeutic Production Value Market Share Comparison (2017 & 2021 & 2028)
Figure 27. United States VS China: Anti-VEGF Therapeutic Production Market Share Comparison (2017 & 2021 & 2028)
Figure 28. United States VS China: Anti-VEGF Therapeutic Consumption Market Share Comparison (2017 & 2021 & 2028)
Figure 29. Key Producers and Market Share of Anti-VEGF Therapeutic in United States
Figure 30. Key Producers and Market Share of Anti-VEGF Therapeutic in China
Figure 31. Key Producers and Market Share of Anti-VEGF Therapeutic in Rest of World
Figure 32. World Anti-VEGF Therapeutic Production Value by Type, (USD Million), 2017 & 2021 & 2028
Figure 33. World Anti-VEGF Therapeutic Production Value Market Share by Type in 2021
Figure 34. Aflibercept (Eylea)
Figure 35. Ranibizumab (Lucentis)
Figure 36. Brolucizumab (Beovu)
Figure 37. Others
Figure 38. World Anti-VEGF Therapeutic Production Market Share by Type (2017-2028)
Figure 39. World Anti-VEGF Therapeutic Production Value Market Share by Type (2017-2028)
Figure 40. World Anti-VEGF Therapeutic Average Price by Type (2017-2028) & (US$/Unit)
Figure 41. World Anti-VEGF Therapeutic Production Value by Application, (USD Million), 2017 & 2021 & 2028
Figure 42. World Anti-VEGF Therapeutic Production Value Market Share by Application in 2021
Figure 43. Macular Edema
Figure 44. Diabetic Retinopathy
Figure 45. Retinal Vein Occlusion
Figure 46. Age-related Macular Degeneration
Figure 47. Others
Figure 48. World Anti-VEGF Therapeutic Production Market Share by Application (2017-2028)
Figure 49. World Anti-VEGF Therapeutic Production Value Market Share by Application (2017-2028)
Figure 50. World Anti-VEGF Therapeutic Average Price by Application (2017-2028) & (US$/Unit)
Figure 51. Manufacturing Cost Structure Analysis of Anti-VEGF Therapeutic in 2021
Figure 52. Manufacturing Process Analysis of Anti-VEGF Therapeutic
Figure 53. Anti-VEGF Therapeutic Industrial Chain
Figure 54. Distribution Channel Breakdown for Anti-VEGF Therapeutic Shipments (%): 2017-2028
Figure 55. Direct Channel Pros & Cons
Figure 56. Indirect Channel Pros & Cons
Figure 57. Methodology
Figure 58. Research Process and Data Source
